The full ondemand investor webcast runs at 21 minutes and is broken down into the following chapters:

1. The urgent unmet medical need and significant market opportunity in difficult-to-control hypertension.
2. The fundamental role of endothelin in hypertension.
3. The clinical evidence that secured TRYVIO’s approval.
4. The details of TRYVIO's differentiated profile in high-risk patient populations.
5. The real-world evidence and market preparation activities currently underway.

Visit the page to also find the slides and transcript.

• Watch the full presentation